Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq:
TVGN), a clinical-stage specialty immunotherapy biotech developing
off-the-shelf, genetically unmodified T cell therapeutics to treat
infectious disease and cancers, is pleased to announce the
appointment of Anthony Tarantino as its new Patient Advocate.
Tarantino, a well-known leader in firefighter safety and community
advocacy, brings extensive experience in representing and
supporting high-risk groups, including first responders.
Anthony Tarantino previously served as President of
the Newark Fire Officers Union and Legislative Vice President of
the Professional Firefighters Association of New Jersey (PFANJ). In
these roles, Tarantino was instrumental in advancing policies for
firefighter health, safety, and wellness. One of his notable
achievements was in advocating for and securing the passage of
legislation in New Jersey mandating regular cancer screenings for
firefighters. This legislation acknowledges the increased risk of
cancer among firefighters due to their exposure to toxic substances
and aims to provide critical early detection and healthcare support
to those serving on the frontlines.
“A Natural Fit for Advocacy”
Ryan Saadi, MD, MPH, Founder and CEO of Tevogen
Bio, highlighted Tarantino’s appointment, stating, “Anthony’s
longstanding dedication to improving the lives of frontline heroes
aligns with our mission of advancing patient-centered healthcare.
His leadership was pivotal in passing cancer screening legislation
for firefighters in New Jersey, providing critical protection to
those who are at increased risk due to their daily exposure to
hazardous environments. His deep understanding of these challenges,
coupled with his ability to advocate effectively at the local and
legislative levels, will help us broaden our efforts to engage and
support patients who face serious health risks, particularly in the
context of immunocompromised cancer patients, the group at high
risk of poor outcomes due to infections. Similar to his long-term
work for cancer advocacy, Anthony will also advocate for those
suffering with Post-Acute Sequelae of SARS-CoV-2, also known as
Long COVID.”
Tarantino’s advocacy work has long been grounded in
the principles of public health, access to life-saving resources,
and legislative engagement. His leadership in the Newark Fire
Officers Union and the PFANJ focused on securing critical health
protections for firefighters, including advocating for improved
safety standards, enhanced benefits for those affected by
occupational hazards, and spearheading cancer screening initiatives
that could be lifesaving for those at increased risk.
“Committed to Patient
Empowerment”
Reflecting on his new role, Tarantino remarked, “My
passion has always been to serve and protect, whether it’s ensuring
the safety of firefighters or advocating for patients who are
navigating complex health conditions. Tevogen’s mission to provide
accessible, life-saving immunotherapies to those most vulnerable
deeply resonates with me, and I am excited to be a part of this
journey.”
Tarantino’s appointment comes at a crucial time as
Tevogen Bio advances its investigational therapy, TVGN 489, for the
treatment of SARS-CoV-2 in cancer patients and those suffering with
Long COVID. With his unique background in frontline safety
advocacy, Tarantino will work closely with multiple stakeholders in
the healthcare ecosystem and Tevogen’s leadership team to amplify
the voice of patients and strengthen outreach programs.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy
company harnessing one of nature’s most powerful immunological
weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf,
genetically unmodified precision T cell therapies for the treatment
of infectious diseases, cancers, and neurological disorders, aiming
to address the significant unmet needs of large patient
populations. Tevogen Leadership believes that sustainability and
commercial success in the current era of healthcare rely on
ensuring patient accessibility through advanced science and
innovative business models. Tevogen has reported positive safety
data from its proof-of-concept clinical trial, and its key
intellectual property assets are wholly owned by the company, not
subject to any third-party licensing agreements. These assets
include three granted patents, nine pending US and twelve ex-US
pending patents, two of which are related to artificial
intelligence.
Tevogen is driven by a team of highly experienced
industry leaders and distinguished scientists with drug development
and global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking
statements, including without limitation statements relating to:
expectations regarding the healthcare and biopharmaceutical
industries; Tevogen’s development of, the potential benefits of,
and patient access to its product candidates for the treatment of
infectious diseases, cancer and neurological disorders, including
TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s
ability to develop additional product candidates, including through
use of Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
and Tevogen’s ability to generate revenue in the future.
Forward-looking statements can sometimes be identified by words
such as “may,” “could,” “would,” “expect,” “anticipate,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this press release and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
Factors that could cause actual results,
performance, or achievements to differ from those expressed or
implied by forward-looking statements include, but are not limited
to: that Tevogen will need to raise additional capital to execute
its business plan, which may not be available on acceptable terms
or at all; the effect of the recent business combination with
Semper Paratus Acquisition Corporation (the “Business Combination”)
on Tevogen’s business relationships, operating results, and
business generally; the outcome of any legal proceedings that may
be instituted against Tevogen; changes in the markets in which
Tevogen competes, including with respect to its competitive
landscape, technology evolution, or regulatory changes; changes in
domestic and global general economic conditions; the risk that
Tevogen may not be able to execute its growth strategies or may
experience difficulties in managing its growth and expanding
operations; the risk that Tevogen may not be able to develop and
maintain effective internal controls; costs related to the Business
Combination and the failure to realize anticipated benefits of the
Business Combination; the failure to achieve Tevogen’s
commercialization and development plans and identify and realize
additional opportunities, which may be affected by, among other
things, competition, the ability of Tevogen to grow and manage
growth economically and hire and retain key employees; the risk
that Tevogen may fail to keep pace with rapid technological
developments to provide new and innovative products and services or
make substantial investments in unsuccessful new products and
services; the ability to develop, license or acquire new
therapeutics; that Tevogen will need to raise additional capital to
execute its business plan, which may not be available on acceptable
terms or at all; the risk of regulatory lawsuits or proceedings
relating to Tevogen’s business; uncertainties inherent in the
execution, cost, and completion of preclinical studies and clinical
trials; risks related to regulatory review, approval and commercial
development; risks associated with intellectual property
protection; Tevogen’s limited operating history; and those factors
discussed or incorporated by reference in Tevogen’s Annual Report
on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Tevogen undertakes no obligation to update any
forward-looking statements, except as required by applicable
law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Tevogen Bio (NASDAQ:TVGN)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024